Literature DB >> 26400962

ATM deficiency promotes development of murine B-cell lymphomas that resemble diffuse large B-cell lymphoma in humans.

Karen S Hathcock1, Hesed M Padilla-Nash2, Jordi Camps3, Dong-Mi Shin4, Daniel Triner1, Arthur L Shaffer5, Robert W Maul6, Seth M Steinberg7, Patricia J Gearhart6, Louis M Staudt5, Herbert C Morse8, Thomas Ried2, Richard J Hodes9.   

Abstract

The serine-threonine kinase ataxia-telangiectasia mutated (ATM) plays a central role in maintaining genomic integrity. In mice, ATM deficiency is exclusively associated with T-cell lymphoma development, whereas B-cell tumors predominate in human ataxia-telangiectasia patients. We demonstrate in this study that when T cells are removed as targets for lymphomagenesis and as mediators of immune surveillance, ATM-deficient mice exclusively develop early-onset immunoglobulin M(+) B-cell lymphomas that do not transplant to immunocompetent mice and that histologically and genetically resemble the activated B cell-like (ABC) subset of human diffuse large B-cell lymphoma (DLBCL). These B-cell lymphomas show considerable chromosomal instability and a recurrent genomic amplification of a 4.48-Mb region on chromosome 18 that contains Malt1 and is orthologous to a region similarly amplified in human ABC DLBCL. Of importance, amplification of Malt1 in these lymphomas correlates with their dependence on nuclear factor (NF)-κB, MALT1, and B-cell receptor (BCR) signaling for survival, paralleling human ABC DLBCL. Further, like some human ABC DLBCLs, these mouse B-cell lymphomas also exhibit constitutive BCR-dependent NF-κB activation. This study reveals that ATM protects against development of B-cell lymphomas that model human ABC DLBCL and identifies a potential role for T cells in preventing the emergence of these tumors.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26400962      PMCID: PMC4643004          DOI: 10.1182/blood-2015-06-654749

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  69 in total

Review 1.  Paradoxical roles of the immune system during cancer development.

Authors:  Karin E de Visser; Alexandra Eichten; Lisa M Coussens
Journal:  Nat Rev Cancer       Date:  2006-01       Impact factor: 60.716

2.  Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction.

Authors:  Silvia Bea; Andreas Zettl; George Wright; Itziar Salaverria; Philipp Jehn; Victor Moreno; Christof Burek; German Ott; Xavier Puig; Liming Yang; Armando Lopez-Guillermo; Wing C Chan; Timothy C Greiner; Dennis D Weisenburger; James O Armitage; Randy D Gascoyne; Joseph M Connors; Thomas M Grogan; Rita Braziel; Richard I Fisher; Erlend B Smeland; Stein Kvaloy; Harald Holte; Jan Delabie; Richard Simon; John Powell; Wyndham H Wilson; Elaine S Jaffe; Emili Montserrat; Hans-Konrad Muller-Hermelink; Louis M Staudt; Elias Campo; Andreas Rosenwald
Journal:  Blood       Date:  2005-07-26       Impact factor: 22.113

3.  MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo.

Authors:  Lorena Fontan; Chenghua Yang; Venkataraman Kabaleeswaran; Laurent Volpon; Michael J Osborne; Elena Beltran; Monica Garcia; Leandro Cerchietti; Rita Shaknovich; Shao Ning Yang; Fang Fang; Randy D Gascoyne; Jose Angel Martinez-Climent; J Fraser Glickman; Katherine Borden; Hao Wu; Ari Melnick
Journal:  Cancer Cell       Date:  2012-12-11       Impact factor: 31.743

4.  A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.

Authors:  Guang Yang; Yangsheng Zhou; Xia Liu; Lian Xu; Yang Cao; Robert J Manning; Christopher J Patterson; Sara J Buhrlage; Nathanael Gray; Yu-Tzu Tai; Kenneth C Anderson; Zachary R Hunter; Steven P Treon
Journal:  Blood       Date:  2013-07-08       Impact factor: 22.113

5.  Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma.

Authors:  Hiroyuki Tagawa; Miyuki Suguro; Shinobu Tsuzuki; Keitaro Matsuo; Sivasundaram Karnan; Koichi Ohshima; Masataka Okamoto; Yasuo Morishima; Shigeo Nakamura; Masao Seto
Journal:  Blood       Date:  2005-05-10       Impact factor: 22.113

Review 6.  Mechanisms of B-cell lymphoma pathogenesis.

Authors:  Ralf Küppers
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

Review 7.  New insights into pre-BCR and BCR signalling with relevance to B cell malignancies.

Authors:  Robert C Rickert
Journal:  Nat Rev Immunol       Date:  2013-08       Impact factor: 53.106

8.  Fas ligand-mediated immune surveillance by T cells is essential for the control of spontaneous B cell lymphomas.

Authors:  Shoukat Afshar-Sterle; Dimitra Zotos; Nicholas J Bernard; Anna K Scherger; Lisa Rödling; Amber E Alsop; Jennifer Walker; Frederick Masson; Gabrielle T Belz; Lynn M Corcoran; Lorraine A O'Reilly; Andreas Strasser; Mark J Smyth; Ricky Johnstone; David M Tarlinton; Stephen L Nutt; Axel Kallies
Journal:  Nat Med       Date:  2014-02-02       Impact factor: 53.440

Review 9.  The biology of human lymphoid malignancies revealed by gene expression profiling.

Authors:  Louis M Staudt; Sandeep Dave
Journal:  Adv Immunol       Date:  2005       Impact factor: 3.543

10.  Incidence, presentation, and prognosis of malignancies in ataxia-telangiectasia: a report from the French national registry of primary immune deficiencies.

Authors:  Felipe Suarez; Nizar Mahlaoui; Danielle Canioni; Chantal Andriamanga; Catherine Dubois d'Enghien; Nicole Brousse; Jean-Philippe Jais; Alain Fischer; Olivier Hermine; Dominique Stoppa-Lyonnet
Journal:  J Clin Oncol       Date:  2014-12-08       Impact factor: 44.544

View more
  7 in total

1.  Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia.

Authors:  Zachary R Hunter; Lian Xu; Nickolas Tsakmaklis; Maria G Demos; Amanda Kofides; Cristina Jimenez; Gloria G Chan; Jiaji Chen; Xia Liu; Manit Munshi; Joshua Gustine; Kirsten Meid; Christopher J Patterson; Guang Yang; Toni Dubeau; Mehmet K Samur; Jorge J Castillo; Kenneth C Anderson; Nikhil C Munshi; Steven P Treon
Journal:  Blood Adv       Date:  2018-11-13

2.  CD40L/IL-4-stimulated CLL demonstrates variation in translational regulation of DNA damage response genes including ATM.

Authors:  Larissa Lezina; Ruth V Spriggs; Daniel Beck; Carolyn Jones; Kate M Dudek; Aleksandra Bzura; George D D Jones; Graham Packham; Anne E Willis; Simon D Wagner
Journal:  Blood Adv       Date:  2018-08-14

3.  Resveratrol and acetyl-resveratrol modulate activity of VEGF and IL-8 in ovarian cancer cell aggregates via attenuation of the NF-κB protein.

Authors:  Alexandria B Tino; Kenny Chitcholtan; Peter H Sykes; Ashley Garrill
Journal:  J Ovarian Res       Date:  2016-12-01       Impact factor: 4.234

4.  SIRT3, a metabolic target linked to ataxia-telangiectasia mutated (ATM) gene deficiency in diffuse large B-cell lymphoma.

Authors:  Kavita Bhalla; Sausan Jaber; Kayla Reagan; Arielle Hamburg; Karen F Underwood; Aditya Jhajharia; Maninder Singh; Binny Bhandary; Shambhu Bhat; Nahid M Nanaji; Ruching Hisa; Carrie McCracken; Heather Huot Creasy; Rena G Lapidus; Tami Kingsbury; Dirk Mayer; Brian Polster; Ronald B Gartenhaus
Journal:  Sci Rep       Date:  2020-12-03       Impact factor: 4.379

5.  In vitro and in vivo anticancer activity of Lycorine in prostate cancer by inhibiting NF-κB signaling pathway.

Authors:  Jie Liu; Shengjun Sun; Cheng Zhou; Zhihong Sun; Qin Wang; Chengming Sun
Journal:  J Cancer       Date:  2022-08-21       Impact factor: 4.478

6.  Conditional abrogation of Atm in osteoclasts extends osteoclast lifespan and results in reduced bone mass.

Authors:  Toru Hirozane; Takahide Tohmonda; Masaki Yoda; Masayuki Shimoda; Yae Kanai; Morio Matsumoto; Hideo Morioka; Masaya Nakamura; Keisuke Horiuchi
Journal:  Sci Rep       Date:  2016-09-28       Impact factor: 4.379

7.  Tia1 dependent regulation of mRNA subcellular location and translation controls p53 expression in B cells.

Authors:  Manuel D Díaz-Muñoz; Vladimir Yu Kiselev; Nicolas Le Novère; Tomaz Curk; Jernej Ule; Martin Turner
Journal:  Nat Commun       Date:  2017-09-13       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.